ArticlemicroPublication biology2026
Identification of GEI-14 as a candidate pro-crossover factor by TurboID in
Article in microPublication biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously, our lab used TurboID-based proximity labeling followed by mass spectrometry (MS) to identify proteins that interact with COSA-1 , a cyclin-like pro-crossover factor that localizes at meiotic crossover sites. Here, we investigated potential interactions of COSA-1 with the top 10 COSA-1 ::TurboID-MS candidates ranked by relative intensity. Beyond the established COSA-1 - CDK-2 interaction, AlphaFold 3 predicted strong binding solely between COSA-1 and GEI-14 . Yeast two-hybrid assays confirmed this interaction and further revealed binding of GEI-14 to MSH-5 , another pro-crossover factor. These results demonstrate TurboID's utility in studying the pro-crossover interactome and highlight GEI-14 as a promising candidate for further characterization.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.